Mythic Therapeutics is a product-platform company developing a pipeline of antibody-drug conjugates (ADCs) designed to exhibit unparalleled therapeutic index and efficacy. The company’s FateControl technology specifically enhances ADC uptake in targeted tissues by manipulating the fate of the ADC within the cell, thereby expanding the disease and patient profiles that can be treated with Mythic’s ADCs.
Location: United States, Massachusetts, Waltham
Total raised: $103M
Investors 8
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.12.2021 | Series B | $103M | - |
Mentions in press and media 4
| Date | Title | Description | Source |
| 16.12.2021 | Reddit is—finally—going public | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
| 15.12.2021 | The top policy battles for 2022, explained | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
| 15.12.2021 | Mythic Therapeutics Launches with New Approach to Improving ... | Mythic Therapeutics today announced its launch to develop smarter and safer antibody-drug conjugates... | marketscre... |
| - | Startup Mythic Therapeutics emerges with $103M to control fa... | The concept of an antibody drug conjugate is straightforward enough: a cancer-killing drug payload a... | medcitynew... |